Full Press Release Details
RiskMetrics and Glass Lewis Endorse All Four Biogen Idec Director Nominees.
BIIB
RiskMetrics and Glass Lewis Endorse All Four Biogen Idec Director Nominees
Key Takeaway: RiskMetrics and Glass Lewis Endorse All Four Biogen Idec Director Nominees
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis